Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.

Willis C, Menon J, Unni S, Au T, Yoo M, Biskupiak J, Brixner D, Ndife B, Joseph G, Bonifacio G, Stein E, Tantravahi S, Shami PJ, Kovacsovics T, Stenehjem D.

Leuk Res. 2019 Dec;87:106262. doi: 10.1016/j.leukres.2019.106262. Epub 2019 Oct 24.

PMID:
31756575
2.

Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis.

Ruiz-Negrón N, Nativi-Nicolau J, Maurer MS, Moran AE, Kovacsovics T, Bellows BK.

Amyloid. 2019;26(sup1):71-72. doi: 10.1080/13506129.2019.1583192. No abstract available.

PMID:
31343305
3.

Chronotropic incompetence and autonomic dysfunction as mechanisms of dyspnoea in patients with late stage cardiac amyloidosis.

Nativi-Nicolau J, Stehlik J, Al-Dulaimi R, Rodriguez C, Jaramillo J, Conte J, Kovacsovics T, Cowley J, Abraham J, Barrel K, Drakos S, Ryan J, Maurer MS, Fang J.

Amyloid. 2019;26(sup1):134-135. doi: 10.1080/13506129.2019.1582024. No abstract available.

PMID:
31343284
4.

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.

Biran N, Siegel D, Berdeja JG, Raje N, Cornell RF, Alsina M, Kovacsovics T, Fang B, Kimball AS, Landgren O.

Am J Hematol. 2019 Jul;94(7):794-802. doi: 10.1002/ajh.25498. Epub 2019 May 13.

5.

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS.

Blood. 2018 Sep 13;132(11):1125-1133. doi: 10.1182/blood-2018-03-841171. Epub 2018 Jul 25.

6.

Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.

Varedi D, Kovacsovics T, Downs Kelly E, Abraham J, Cowley J, Barrell K, Revelo MP, Stehlik J, Drakos S, Marrouche N, Wilson B, Swanson EA, Fang J, Nativi-Nicolau J.

Circ Heart Fail. 2018 Jul;11(7):e004812. doi: 10.1161/CIRCHEARTFAILURE.117.004812. No abstract available.

PMID:
29921704
7.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
8.

Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.

Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, Kovacsovics TJ, Marth GT, O'Hare T, Deininger MW.

Leukemia. 2018 Sep;32(9):2049-2054. doi: 10.1038/s41375-018-0050-z. Epub 2018 Mar 27. No abstract available.

9.

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.

Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, Ahorukomeye P, Glenn MJ, Deininger MWN, Boucher KM, Bavisotto LM, Gutierrez-Sanchez G, Kennedy TP, Marcus SG, Shami PJ.

Blood Adv. 2018 Feb 27;2(4):381-389. doi: 10.1182/bloodadvances.2017013391.

10.

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS.

Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.

11.

MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk.

Juster-Switlyk K, Smith AG, Kovacsovics T, Stephens D, Glenn M, Palmer CA, Quigley EP 3rd, Kolb N.

Neurology. 2017 Feb 7;88(6):603-604. doi: 10.1212/WNL.0000000000003590. Epub 2017 Jan 6. No abstract available.

12.

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.

Gordon MJ, Tardi P, Loriaux MM, Spurgeon SE, Traer E, Kovacsovics T, Mayer LD, Tyner JW.

Leuk Res. 2017 Feb;53:39-49. doi: 10.1016/j.leukres.2016.12.002. Epub 2016 Dec 12.

PMID:
28013106
13.

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner JW, Wong M, Druker BJ.

Cancer Res. 2016 Nov 15;76(22):6471-6482. doi: 10.1158/0008-5472.CAN-15-3569. Epub 2016 Sep 26.

14.

A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.

Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW.

Leuk Lymphoma. 2016 Oct;57(10):2441-4. doi: 10.3109/10428194.2016.1138295. Epub 2016 Feb 8. No abstract available.

15.

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.

Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D.

Hum Vaccin Immunother. 2015;11(7):1606-11. doi: 10.1080/21645515.2015.1046658.

16.

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients.

Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Kröger N, Luetkens T, Atanackovic D.

Blood Cancer J. 2015 Mar 6;5:e285. doi: 10.1038/bcj.2015.7. No abstract available.

17.

Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.

Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT.

Biol Blood Marrow Transplant. 2015 Jan;21(1):89-96. doi: 10.1016/j.bbmt.2014.09.024. Epub 2014 Oct 16.

18.

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ.

Blood. 2014 May 22;123(21):3239-46. doi: 10.1182/blood-2013-12-540971. Epub 2014 Mar 31.

19.

Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.

Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):424-430.e1. doi: 10.1016/j.clml.2014.02.003. Epub 2014 Feb 16.

PMID:
24650974
20.

Functional integration of acute myeloid leukemia into the vascular niche.

Cogle CR, Goldman DC, Madlambayan GJ, Leon RP, Masri AA, Clark HA, Asbaghi SA, Tyner JW, Dunlap J, Fan G, Kovacsovics T, Liu Q, Meacham A, Hamlin KL, Hromas RA, Scott EW, Fleming WH.

Leukemia. 2014 Oct;28(10):1978-1987. doi: 10.1038/leu.2014.109. Epub 2014 Mar 18.

21.

Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM.

Cancer Res. 2013 Jan 1;73(1):285-96. doi: 10.1158/0008-5472.CAN-12-1906. Epub 2012 Oct 18.

22.

Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.

Dunlap J, Beadling C, Warrick A, Neff T, Fleming WH, Loriaux M, Heinrich MC, Kovacsovics T, Kelemen K, Leeborg N, Gatter K, Braziel RM, Press R, Corless CL, Fan G.

Hum Pathol. 2012 Dec;43(12):2167-76. doi: 10.1016/j.humpath.2012.03.002. Epub 2012 Jun 1.

PMID:
22658276
23.

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM.

J Clin Oncol. 2012 Jul 10;30(20):2492-9. doi: 10.1200/JCO.2011.37.9743. Epub 2012 May 14.

24.

RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia.

Kelemen K, Kovacsovics T, Braziel R, Corless C, Beadling C, Fan G.

Leuk Lymphoma. 2012 May;53(5):999-1002. doi: 10.3109/10428194.2011.634047. Epub 2011 Dec 7. No abstract available.

PMID:
22035377
25.

Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.

Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, Gabrilove J, Huebner D, Gandhi PJ, Kantarjian H; CLASSIC II Investigators.

Leuk Lymphoma. 2012 Mar;53(3):435-40. doi: 10.3109/10428194.2011.616960. Epub 2011 Oct 24.

26.

Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.

Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, Bleyer A.

Leuk Lymphoma. 2011 Dec;52(12):2237-53. doi: 10.3109/10428194.2011.596963. Epub 2011 Aug 10.

PMID:
21827361
27.

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, Bedalov A, Sanders JE, Pagel JM, Sickle EJ, Witherspoon R, Flowers ME, Appelbaum FR, Deeg HJ.

Biol Blood Marrow Transplant. 2011 Mar;17(3):341-50. doi: 10.1016/j.bbmt.2010.05.007. Epub 2010 May 26.

28.

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, Selleslag D, Schouten HC, Ferrant A, Biersack H, Amadori S, Muus P, Jansen JH, Hellström-Lindberg E, Kovacsovics T, Wijermans P, Ossenkoppele G, Gratwohl A, Marie JP, Willemze R.

Haematologica. 2010 Oct;95(10):1754-61. doi: 10.3324/haematol.2009.019182. Epub 2010 May 21.

29.

RNAi screen for rapid therapeutic target identification in leukemia patients.

Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ.

Proc Natl Acad Sci U S A. 2009 May 26;106(21):8695-700. doi: 10.1073/pnas.0903233106. Epub 2009 May 11.

30.

Peritoneal tuberculosis after imatinib therapy.

Senn L, Kovacsovics T, Tarr PE, Meylan P.

Arch Intern Med. 2009 Feb 9;169(3):312-3. doi: 10.1001/archinternmed.2008.581. No abstract available.

PMID:
19204223
31.

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience.

Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K, Nelson V, Kovacsovics T, Leis J, Calandra G, Maziarz RT.

Bone Marrow Transplant. 2009 Jun;43(12):909-17. doi: 10.1038/bmt.2008.409. Epub 2009 Feb 2.

PMID:
19182831
32.

Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.

Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T.

Ann Hematol. 2009 Jul;88(7):681-5. doi: 10.1007/s00277-008-0652-z. Epub 2008 Dec 6.

PMID:
19066891
33.

High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia.

Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, MacPartlin M, Willis SG, Lange T, Druker BJ, Kovacsovics T, Maziarz R, Gattermann N, Deininger MW.

Leukemia. 2009 Feb;23(2):406-9. doi: 10.1038/leu.2008.187. Epub 2008 Jul 10. No abstract available.

PMID:
18615102
34.

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.

Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Dombret H, Thomas X; GET-LALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group.

Leukemia. 2007 Sep;21(9):1907-14. Epub 2007 Jul 5.

PMID:
17611565
36.

Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.

Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsovics T, Kosinski M, Mach JP, Ketterer N.

Br J Cancer. 2006 Jun 19;94(12):1770-6. Epub 2006 May 9.

37.

Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials.

Dhédin N, Dombret H, Thomas X, Lhéritier V, Boiron JM, Rigal-Huguet F, Vey N, Kuentz M, Reman O, Witz F, Delannoy A, Kovacsovics T, Bradstock K, Charrin C, Boucheix C, Gabert J, Blaise D, Fière D, Vernant JP.

Leukemia. 2006 Feb;20(2):336-44.

PMID:
16357838
38.

Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.

Gambillara E, Laffitte E, Widmer N, Decosterd LA, Duchosal MA, Kovacsovics T, Panizzon RG.

Dermatology. 2005;211(4):363-5.

PMID:
16286749
39.

Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics.

Antonescu C, Bischof Delaloye A, Kosinski M, Monnin P, Schaffland AO, Ketterer N, Grannavel C, Kovacsovics T, Verdun FR, Buchegger F.

Eur J Nucl Med Mol Imaging. 2005 Aug;32(8):943-51. Epub 2005 Apr 12.

PMID:
15824926
40.

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Fiere D.

J Clin Oncol. 2004 Oct 15;22(20):4075-86. Epub 2004 Sep 7.

PMID:
15353542
41.

Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics.

Beyer V, Castagné C, Mühlematter D, Parlier V, Gmür J, Hess U, Kovacsovics T, Meyer-Monard S, Tichelli A, Tobler A, Jacky E, Schanz U, Bargetzi M, Hagemeijer A, de Witte T, van Melle G, Jotterand M.

Cancer Genet Cytogenet. 2004 Jul 1;152(1):29-41.

PMID:
15193439
42.

Developing a European network for adult ALL.

Gökbuget N, Bassan R, Dekker A, Dombret H, Foà R, Ifrah N, Kovacsovics T, Labar B, Mandelli F, Meloni G, Ribera JM, Smedmyr B, Vernant JP, Walewski J, Willemze R, Hoelzer D; European Working Group for Adults ALL (EWALL).

Hematol J. 2004;5 Suppl 3:S46-52. No abstract available.

PMID:
15190278
43.

A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation.

Hauert J, Fernandez-Carneado J, Michielin O, Mathieu S, Grell D, Schapira M, Spertini O, Mutter M, Tuchscherer G, Kovacsovics T.

Chembiochem. 2004 Jun 7;5(6):856-64.

PMID:
15174170
44.

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

Widmer N, Béguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, Leyvraz S, Rosselet A, Biollaz J, Decosterd LA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):285-92.

PMID:
15063337
45.

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T.

Blood. 2004 Jun 15;103(12):4416-23. Epub 2004 Feb 19.

PMID:
14976046
46.

Recurrent cytomegalovirus disease, visceral leishmaniosis, and Legionella pneumonia after liver transplantation: a case report.

Halkic N, Ksontini R, Scholl B, Blanc C, Kovacsovics T, Meylan P, Muheim C, Gillet M, Mosimann F.

Can J Anaesth. 2004 Jan;51(1):84-7.

PMID:
14709468
47.

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.

Löwenberg B, van Putten W, Theobald M, Gmür J, Verdonck L, Sonneveld P, Fey M, Schouten H, de Greef G, Ferrant A, Kovacsovics T, Gratwohl A, Daenen S, Huijgens P, Boogaerts M; Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research.

N Engl J Med. 2003 Aug 21;349(8):743-52.

48.

Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.

Sonneveld P, Burnett A, Vossebeld P, Ben-Am M, Rosenkranz G, Pfister C, Verhoef G, Dekker A, Ossenkoppele G, Ferrant C, Yin L, Gratwohl A, Kovacsovics T, Vellenga E, Capdeville R, Löwenberg B.

Hematol J. 2000;1(6):411-21.

PMID:
11920222
49.

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjønnfjord G, Bekradda M, Itzhaki M, Hérait P.

J Clin Oncol. 2002 Jan 1;20(1):205-13.

PMID:
11773171
50.

Acute myeloid leukemia in the elderly: results of an individualized approach in two centres.

Spataro V, Kovacsovics T, Bach S, Pampallona S, Schapira M, Cavalli F.

Leuk Lymphoma. 2000 Nov;39(5-6):521-30.

PMID:
11342335

Supplemental Content

Loading ...
Support Center